TP53 and leukemia: Thus, by the time patients are candidates for CAR T cell therapy, they are likely to harbor leukemias that have acquired mutations (i.e., TP53 mutations and complex cytogenetic abnormalities) rendering them resistant to treatment, as well as potentially rapidly progressing with symptomatic disease by the time they require CAR T cell therapy.